Do peptides show up on a drug test? Workplace panels vs WADA

The standard 5 panel covers amphetamines, cocaine metabolites, marijuana, opiates and phencyclidine. The federal workplace program, which sets the pattern for regulated industries, uses that panel with an expanded opioid group that includes oxycodone, hydrocodone, hydromorphone and oxymorphone. A 10 panel adds benzodiazepines, barbiturates, methadone and a few others depending on the lab. The method is an immunoassay screen, where an antibody designed for one drug class binds it in urine, followed by confirmation of any positive by mass spectrometry. Each target needs its own antibody, and no workplace panel includes one for ipamorelin, BPC-157 or any other peptide.

Hair, saliva and blood tests used by employers target the same drug classes. A pre-employment screen, a random test and a post-accident test all draw from the same menu. The one way a peptide shows up indirectly is through a medical, not a drug test: a wellness panel that includes IGF-1 will reflect a secretagogue, and fasting glucose can drift on growth hormone compounds. That is a conversation with a doctor, not a positive result. Insulin syringes found in a bag are also a conversation, not a test.

The WADA Prohibited List is updated every January 1 and applies to every sport under the World Anti-Doping Code, including Olympic sports, most professional leagues that adopt it, and collegiate systems that mirror its classes. Two sections do the work for peptides. S0 covers non-approved substances: any pharmacological substance with no current approval by a governmental regulatory authority for human therapeutic use. WADA has named BPC-157 as an S0 example, and investigational drugs like retatrutide and cagrilintide sit there until approval. S2 covers peptide hormones, growth factors and related substances: growth hormone and its fragments and analogs, growth hormone secretagogues like ipamorelin and the GHRPs, GHRH analogs like CJC-1295, sermorelin and tesamorelin, IGF-1 and its analogs, and thymosin beta-4 and its derivatives, with TB-500 named explicitly. Both sections are prohibited at all times, not only in competition.

The compounds not named on the list as of 2026 include the approved GLP-1 drugs semaglutide and tirzepatide, melanotan-1 and melanotan-2, PT-141, GHK-Cu, KPV, Semax, Selank, epithalon, DSIP, glutathione and NAD+. One caution belongs here. S0 is a catch-all, and a compound with no approval anywhere can fall under it without being named, so not listed on a compound page means not named, not cleared. A tested athlete with a specific question should check the current list and the Global DRO database that several anti-doping agencies maintain, rather than a page that was accurate in October 2026.

A detection window depends on half-life, dose, route, whether blood or urine is tested, and how sensitive the lab method is, which is why published figures move. The short acting compounds clear blood fast: ipamorelin has a plasma half-life of about two hours, CJC-1295 without DAC about 30 minutes, and sermorelin 10 to 20 minutes. Labs do not rely on the parent peptide, though. Published doping control methods target characteristic urinary metabolites of the GHRPs, and reported windows for those are on the order of a day or two after a dose. The DAC version of CJC-1295 has a half-life measured in days and is detectable for correspondingly longer.

TB-500 is the compound with the most developed testing history, because horse racing authorities built methods for it in equine urine and plasma years ago, and human methods followed. The fragment's plasma half-life is one to two hours, with clearance in about 12 hours, but its metabolites extend the urinary window to days. BPC-157 has a plasma half-life under 30 minutes and published detection methods exist; reported windows are short. Growth hormone is tested two ways, an isoform test with a window of roughly a day or two, and a biomarker test using IGF-1 and a collagen marker that extends to weeks.

The caveat that matters more than any window is retesting. Anti-doping samples can be stored for up to ten years and reanalyzed when a better method arrives, and sanctions have followed from exactly that. Clean at the time of the test is not a permanent state for a stored sample.

The US military drug testing program screens for a broader set than a civilian 5 panel, including synthetic cannabinoids and several prescription drugs, but it is still a drugs of abuse panel and does not include peptides. What is different in the military is policy rather than chemistry. Service regulations prohibit using prescription drugs without a prescription and restrict unapproved substances, so possession of research peptides can be a disciplinary question even when no test would ever find them. The same applies, less formally, to police and fire departments with conduct policies, a few of which also run anabolic steroid panels. Those steroid panels are specific to steroids and do not include peptides.

Expanded employer panels of 12 to 14 drugs add things like tramadol, fentanyl, buprenorphine and oxycodone. Healthcare employers add drugs that staff have access to. None of these include a peptide, for the same reason as the basic panel: there is no immunoassay for one and no employer has a reason to pay for mass spectrometry targeting ipamorelin. The practical answer for employees is that a research peptide will not be found, and a GLP-1 drug is a prescription medicine that no panel looks for either.

For anyone whose only testing is an employer, the answer is the whole list: no peptide on this site is a workplace drug test concern. For a tested athlete the list sorts into three groups.

The employee facing a pre-employment or random screen: no. The panel does not include peptides and cannot detect them. The only exposure is a medical exam that includes bloodwork, or a policy about unapproved substances that most employers do not have.

The tested athlete: assume every compound in the healing and growth hormone classes is detectable and prohibited at all times, that stop times quoted on forums are guesses against a moving target, and that a stored sample can be reanalyzed years later. Collegiate systems follow similar classes, with peptide hormones and growth factors banned. The GLP-1 drugs are not prohibited, but a compounded or grey market vial carries its own purity risk, and a contaminated vial is a doping case nobody planned. Are peptides safe covers that purity problem.

The service member or officer: the test will not find it, but the conduct policy may apply, and that is a question for the regulation, not the lab. Traveling with peptides covers the related customs exposure, which is the other way a research peptide becomes an official problem without any test being run.